THE SCIENCE
BEHIND Feiolix®

A clinically-validated whole fruit freeze-dried
Feijoa powder for metabolic balance.

Feiolix® is a proprietary freeze-dried powder derived from the fruit of Acca sellowiana, developed to restore insulin sensitivity and improve cardiometabolic health through multi-pathway biological activity.

WHAT’S SO SPECIAL
ABOUT Feiolix®?

Feiolix® is a natural GLP-1 agonist with three key pathways to support GLP-1 secretion.

Backed by emerging human clinical research, Feiolix® delivers measurable outcomes across:

  • Glycaemic control
  • Endogenous GLP-1 signalling
  • Lipid regulation
  • Weight management
  • Thermogenesis
  • Inflammatory regulation
  • Appetite modulation

Feiolix® is positioned as a next-generation metabolic ingredient platform, not a single-mechanism botanical.

Whole and halved feijoas with green leaves on a white background
Timeline chart of Feiolix research milestones and clinical studies

Clinical Evidence

4

clinical studies

3

randomised controlled trials

1

open-label study

2

peer-reviewed publications

Hand using a blood glucose meter showing a reading

StUDY 1NE.

Feiolix Metabolic Health Study

Participants: 39 overweight adults with prediabetes
Dose: 300 mg (low dose) or 1,150 mg (high dose) daily
Design: 12-week randomised, double-blind, placebo-controlled trial
Results vs placebo:

  • Lower HbA1c at both doses
  • Improved insulin sensitivity: lower HOMA-IR and fasting insulin at both doses
  • Better cholesterol: lower LDL and total cholesterol at both doses
  • High dose: limited triglyceride rise, with modest reductions in weight and BMI
  • Low dose: limited fasting glucose rise
  • Well tolerated: no treatment-related adverse events
Feet on a bathroom scale above a yellow measuring tape

StUDY 2wo.

FERDINAND Study

Participants: 97 adults with prediabetes and overweight or obesity
Dose: 1,150 mg daily for 6 months
Design: 6-month randomised, double-blind, placebo-controlled trial (2-month low-energy diet, then 4-month weight maintenance)
Results vs placebo:

Woman at a kitchen table checking her blood glucose with a meter

StUDY 3hree.

Feiolix Extract Study in Type 2 Diabetes

Participants: 34 adults aged 40 to 75 with type 2 diabetes
Dose: 150 mg Feiolix extract daily (equivalent to about 2,300 mg Feiolix powder)
Design: 12-week randomised, double-blind, placebo-controlled trial
Results vs placebo:

  • Lower fasting glucose and HbA1c
  • Lower triglycerides and total cholesterol
  • Blood pressure: systolic and diastolic decreased with Feiolix, while rising slightly with placebo
  • Well tolerated: no adverse effects reported
Woman at a kitchen table checking her blood glucose with a meter

StUDY 4our.

Feiolix Safety Study in Type 2 Diabetes

Participants: 15 adults with type 2 diabetes
Dose: 2,300 mg daily
Design: 12-week open-label study
Results:

  • Well tolerated: no changes in blood counts, blood chemistry, or liver and kidney function
  • Lower HbA1c over 12 weeks

The Health Benefits of Feijoa –
Mechanistically Defined.

The fruit of Acca sellowiana contains a rare combination of bioactives that act synergistically on metabolic pathways.

Feiolix® concentrates three major bioactive classes:

Close-up of freshly picked green feijoas

Abscisic Acid.

Insulin Sensitivity & GLP-1 Modulation

Abscisic acid (ABA) is a conserved signalling molecule found in both plants and humans.

In human physiology, ABA:

  • Binds to LANCL2 receptors
  • Enhances glucose-dependent insulin secretion
  • Stimulates peripheral glucose uptake
  • Promotes endogenous GLP-1 release
  • Increases mitochondrial gene expression
  • Activates brown adipose tissue
  • Enhances thermogenesis
  • ABA works in a glucose-dependent manner, supporting metabolic regulation without overstimulation.
Close-up of freshly picked green feijoas

Ellagitannins > Urolithins.

Inflammation Control & Mitochondrial Function

Feijoa is naturally rich in pedunculagin, an ellagitannin converted by gut microbiota into bioactive urolithins.
Urolithins:

  • Reduce pro-inflammatory cytokines
  • Improve insulin signalling pathways
  • Promote GLP-1 secretion through bitter taste receptors
  • Enhance mitochondrial efficiency
  • Promote browning of white adipose tissue
  • Support adipose tissue remodelling

Chronic low-grade inflammation is a key driver of insulin resistance. Feiolix® targets this upstream mechanism.

Close-up of freshly picked green feijoas

Xyloglucan Fibre Matrix.

Glycaemic Modulation & Gut-Metabolic Axis

Abscisic acid (ABA) is a conserved signalling molecule found in both plants and humans.

Xyloglucans are specialised hemicellulose fibres that:

  • Slow glucose absorption
  • Reduce post-prandial spikes
  • Support bile acid metabolism
  • Improve triglyceride clearance
  • Increase production of propionate via fermentation

Propionate is associated with:

  • Improved satiety signalling
  • Reduced caloric intake
  • Enhanced GLP-1 stimulation
  • This gut-metabolic interaction differentiates Feiolix® from isolated ABA ingredients.

THE Feiolix® FACTS.

GLP-1 & Blood
sugar spikes.

When you eat, carbohydrates are broken down into glucose, which enters your bloodstream and causes your blood sugar to rise.

In response, your gut releases hormones like GLP-1 that tell the pancreas to release insulin, reduce glucagon, slow stomach emptying and signal to your brain that you’re getting full.

In a healthy response, blood sugar rises moderately after a meal, GLP-1 and insulin help move glucose into muscles and other tissues, and your levels drift back toward baseline over 2–3 hours without a hard “crash.”

When this system is overloaded by frequent, large spikes—think high-sugar or refined-carb meals—your pancreas has to work harder, insulin levels surge, and over time cells can become less responsive to insulin, a process known as insulin resistance.

These sharp spikes and rapid drops also drive hunger, cravings, low energy, and long-term cardiometabolic risk, which is why moderating post-meal blood sugar and supporting robust GLP-1 signalling are central to modern metabolic health strategies.

Feiolix® is a natural GLP-1 agonist that amplifies your body’s own GLP-1 signalling rather than acting as a single synthetic receptor agonist.

Through its ABA, ellagitannin–urolithin and xyloglucan fibre matrix, Feiolix® promotes endogenous GLP-1 release from gut and pancreatic cells, supports GLP-1 receptor activation, and enhances downstream effects on insulin secretion, satiety signalling and thermogenesis.

This multi-pathway GLP-1 support translates into more stable post-prandial glycaemic responses, reduced appetite, and improved metabolic efficiency without overstimulating glucose-independent pathways.

Feiolix® &
BLOOD SUGAR SPIKES.

Post-meal blood sugar spikes and rapid crashes are central drivers of insulin resistance, hunger, and long-term cardiometabolic risk.

By slowing glucose absorption via its xyloglucan-rich fibre matrix, stimulating GLP-1 and PYY release through gut–microbiome interactions, and improving peripheral glucose uptake via ABA and urolithins, Feiolix® smooths the post-prandial glucose curve rather than simply lowering fasting glucose.

In controlled CGM consumer studies, Feiolix® reduced 30 minute glucose peaks by up to ~35% at breakfast and up to ~50% with high-GI snacks, while extending sustained glucose stability for 21–47%, supporting steadier energy, reduced cravings and a lower glycaemic burden over time.

Woman scanning a continuous glucose monitor on her upper arm with a phone
Person holding the waistband of loose trousers

Multi-Pathway
Mechanism of Action.

Feiolix® operates across five coordinated pathways:

1. Glucose-dependent insulin sensitisation

2. Endogenous GLP-1 modulation

3. Thermogenic activation

4. Inflammatory reduction

5. Gut-metabolic axis regulation

This systems-level activity supports sustainable metabolic restoration throughout the body rather than a single-target intervention.
Clinically, this is reflected in improvements in HbA1c, fasting glucose, lipids, blood pressure, visceral fat and satiety, aligning Feiolix® with current priorities in metabolic health and positioning it as a next-generation GLP-1 supportive ingredient for long-term metabolic balance.

Cardiometabolic
Health Impact.

Across studies, Feiolix® demonstrates improvements in:

  • HbA1c
  • Fasting glucose
  • Insulin sensitivity
  • Triglycerides
  • LDL cholesterol
  • Blood pressure
  • Visceral fat markers
  • Inflammatory biomarkers

These outcomes align with current clinical priorities in metabolic health management.

**In the FERDINAND trial (2026), systolic blood pressure was lower with Feiolix than with placebo at 4 and 6 months

Bowl of feijoas with a measuring tape and green dumbbells on a mint background
Stacked stainless steel shelves reflecting light, as used in freeze drying

Target Bio-Lock™
Technology.

Feiolix® is produced using proprietary Target Bio-Lock™ processing technology.

This ensures:

  • Stability of abscisic acid
  • Preservation of polyphenols
  • Maintenance of fibre architecture
  • Standardised bioactive consistency

Target Bio-Lock™ protects the natural fruit matrix synergy critical to efficacy.

Strategic Positioning
Opportunities.

Feiolix® supports innovation in:

  • Blood glucose management
  • GLP-1 supportive nutrition
  • Metabolic syndrome formulations
  • Weight management systems
  • Women’s metabolic health
  • Cardiometabolic health blends

For formulation concepts, claim frameworks and technical documentation, visit our NPD Support section.

Woman in sportswear lifting a red dumbbell
Scientist using a microscope in a laboratory

A Clinically
Advancing Metabolic
Platform.

Feiolix® combines:

  • A whole-fruit bioactive matrix
  • Mechanistic validation
  • Human clinical data
  • Multi-pathway metabolic activity

Positioned at the intersection of nutrition science and metabolic restoration, Feiolix® enables next-generation metabolic health solutions.

How
FeiolIX®
Works

The
Science

get
support

get in
touch

Let’s Formulate the Next Generation
of Metabolic Health Solutions.

Whether you are developing GLP-1–focused solutions, blood glucose support or weight management products, Feiolix® offers a natural, whole-fruit approach to metabolic health.